Edwin A. Saada

Medicine · Health Sciences

18h-index923citations32works13.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Trypanosoma species research and implications(11), SARS-CoV-2 and COVID-19 Research(7), CRISPR and Genetic Engineering(6), Insect symbiosis and bacterial influences(5), Computational Drug Discovery Methods(4)

Publications32 total

Machine Learning Models Assisting the Development of Antibody Therapeutics and Vaccines – an Emerging Trend
Underline Science Inc.·2026Open Access
Computationally restoring the potency of a clinical antibody against Omicron
Nature·2024· 39 citedOpen Access
Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies
PLoS ONE·2024Open Access
Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies
2023Open Access
Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins
Scientific Reports·2023· 34 citedOpen Access
Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
2022· 5 citedOpen Access
High-throughput virtual screening of small molecule inhibitors for SARS-CoV-2 protein targets with deep fusion models
2021· 2 citedOpen Access
Immunocompromised Cas9 transgenic mice for rapid in vivo assessment of host factors involved in highly pathogenic virus infection
Molecular Therapy — Methods & Clinical Development·2021· 2 citedOpen Access
Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline
Frontiers in Molecular Biosciences·2021· 27 citedOpen Access
Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies
2021· 1 citedOpen Access
High-Throughput Virtual Screening of Small Molecule Inhibitors for\n SARS-CoV-2 Protein Targets with Deep Fusion Models
arXiv (Cornell University)·2021· 1 citedOpen Access
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
mAbs·2021· 21 citedOpen Access
Corrigendum to “Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery” Acta Biomaterialia (2020), 114, 358-368
Acta Biomaterialia·2020· 1 cited
COVID-19 Infection Prevention through Natural Product Molecules
2020Open Access
Identification of Positive Chemotaxis in the Protozoan Pathogen Trypanosoma brucei
mSphere·2020· 25 citedOpen Access
Development and delivery of RNA-targeting CRISPR systems for anti-viral countermeasures.
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2020Open Access
Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery
Acta Biomaterialia·2020· 99 citedOpen Access
Identification of positive chemotaxis in the protozoan pathogen <i>Trypanosoma brucei</i>
2019· 2 cited
Use of anti-CRISPR protein AcrIIA4 as a capture ligand for CRISPR/Cas9 detection
Biosensors and Bioelectronics·2019· 29 citedOpen Access
Versatile High-Throughput Fluorescence Assay for Monitoring Cas9 Activity
Analytical Chemistry·2018· 24 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Kent L. Hill(11), Oscar Negrete(9), Brooke Harmon(8), Joseph S. Schoeniger(7), Adam Zemła(7), Dina R. Weilhammer(7), Brent W. Segelke(7), James A. Wohlschlegel(6), Feliza Bourguet(6), Gerasimos Langousis(5), Michelle M. Shimogawa(5), Edmond Y. Lau(5), Fangqiang Zhu(5), Jacky Lo(5), Nicole M. Collette(5), Monica K. Borucki(5), Maxwell Stefan(5), Jonathan Allen(5), Ajay A. Vashisht(4), Kathryn T. Arrildt(4)